Related by context. All words. (Click for frequent words.) 80 oral kinase inhibitor 65 MGCD# [002] 64 investigational humanized monoclonal antibody 64 c MET 64 hypoxia activated prodrug 64 protein kinase inhibitor 64 sodium glucose cotransporter 64 selective kinase inhibitor 64 dasatinib Sprycel ® 63 multi kinase inhibitor 63 investigational monoclonal antibody 63 CYT# potent vascular disrupting 63 XL# XL# XL# 63 sunitinib Sutent ® 63 PLX MS 63 alpha folate receptor 63 ENMD # 63 oral prodrug 62 Carfilzomib 62 pan HDAC inhibitor 62 RAS MAPK pathway 62 familial amyloidotic polyneuropathy FAP 62 RGB # 62 mertansine 62 molecules Immune SIMULATORS 62 M2 subunit 62 imatinib Gleevec ® 62 myelofibrosis polycythemia vera 62 Cobalamin TM mediated 62 c Raf kinase 62 novel VDA molecule 62 erlotinib Tarceva ® 62 PNP inhibitor 62 JAK1 62 tyrosine kinase inhibitor 61 including HGF ErbB3 61 ALK inhibitor 61 IgG1 monoclonal antibody 61 receptor tyrosine kinase inhibitor 61 XL# XL# 61 AEG# 61 IAP inhibitor 61 colorectal bladder 61 kidney urologic 61 proteasome inhibitor 61 histone deacetylase HDAC inhibitor 61 VEGFR2 inhibitor 61 MCSP respectively 60 Enzastaurin 60 sodium thiosulfate STS 60 Additional BiTE antibodies 60 Aurora kinase 60 PI3K/Akt pathway inhibitor 60 EGFR HER2 60 LHRH antagonists 60 elotuzumab 60 nilotinib Tasigna ® 60 orally administered inhibitor 60 ALN TTR 60 anticancer compound 60 HuLuc# 60 HER2 positive metastatic breast 60 docetaxel Taxotere R 60 bevacizumab Avastin ® 60 kinase inhibitor 59 CEA CD# Her2 59 CD# monoclonal antibody 59 including eniluracil ADH 59 RNAi therapeutic targeting 59 AKT inhibitor 59 Exelixis compounds 59 humanized monoclonal antibody 59 VEGFR 59 DG# compounds targeting 59 orally bioavailable 59 alvespimycin 59 essential thrombocythemia ET 59 CCR9 antagonist 59 novel histone deacetylase 59 taxane derivative 59 Elotuzumab 59 JAK inhibitor 59 AQ4N 59 Sym# 59 HDACi 59 CEQ# 59 IMA# 59 castrate resistant prostate cancer 59 synthetic cannabinoid library 59 HGS ETR1 mapatumumab 59 small molecule tyrosine 59 MT# MEDI 59 ribonucleotide reductase clinically validated 59 cetuximab Erbitux R 59 tumor xenograft models 58 Cloretazine R 58 metastatic colorectal 58 mitogen activated ERK kinase 58 Atiprimod 58 targeting CD# 58 humanized anti 58 delta isoform 58 Akt inhibitor 58 selective inhibitor 58 phase IIb clinical 58 Janus Kinase 58 huC# DM4 58 VEGF receptors 58 angina nausea 58 cell lymphoma CTCL 58 Blinatumomab 58 enhance ApoA 58 Annamycin 58 HGS ETR1 58 hypoxia inducible factor 58 GRN#L 58 CCX# 58 Exherin TM 58 ATC ovarian cancer 58 Panzem R NCD 57 hormone gastrin 57 Phase Ib clinical trials 57 metaglidasen 57 sarcoma melanoma 57 OncoVEX GM CSF 57 Phase #b/#a clinical 57 Epratuzumab 57 nucleoside analog 57 antiangiogenesis therapies 57 MEK inhibitors 57 VEGF receptor 57 angiogenesis inhibitor 57 vascular disrupting agent 57 HDAC Inhibitor 57 Xanafide 57 Nasdaq HALO biopharmaceutical 57 vinca alkaloid 57 CYC# 57 Perifosine 57 polymerase inhibitor 57 Hedgehog Pathway Inhibitor 57 reversible inhibitor 57 volociximab 57 Vandetanib 57 Hsp# Inhibitor 57 Tarvacin TM 57 OXi# 57 antibody MAb 57 HCV polymerase 57 SCH # 57 liposomal formulation 57 PORxin TM 57 PI3K/mTOR 57 MEK inhibitor 57 IRX 2 57 small molecule inhibitor 57 insomnia migraine headaches 57 monoclonal antibody MAb 57 myeloproliferative diseases 57 TG# [003] 57 R sorafenib tablets 57 alkylating agent 57 Chronic Lymphocytic Leukemia CLL 57 Vicinium TM 57 Bortezomib 57 neovascular diseases 56 epithelial tumors 56 rNAPc2 56 entinostat 56 cutaneous T 56 recurrent NSCLC 56 kinase inhibition 56 Pralatrexate 56 hematological cancers 56 dasatinib Sprycel 56 poly ADP ribose polymerase 56 Smac mimetics 56 hematological malignancies 56 Symadex 56 leukemia AML 56 pertuzumab 56 BRAF inhibitor 56 protein kinase inhibitors 56 Hsp# inhibition 56 enzastaurin 56 ALN VSP 56 advanced metastatic renal 56 Proxinium TM 56 FLT3 56 small molecule inhibitors 56 glioblastoma multiforme GBM 56 cutaneous T cell 56 pips #,# +# pips 56 JAK inhibitors 56 Apaziquone 56 HGS ETR2 56 radiation sensitizer 56 signal transduction inhibitor 56 apoptotic pathway 56 Insegia 56 BAY #-# 56 pheochromocytoma 56 relapsed acute myelogenous 56 LHRH receptor positive 56 gefitinib Iressa 56 ELACYT 56 VEGFR2 56 Omacetaxine 56 IMC #B 56 TELINTRA 56 xenograft models 56 prostate cancer antigen prostatic 56 subcutaneous formulation 56 immunomodulating 56 therapeutic peptide 56 immunomodulator 55 Vidofludimus 55 sPLA2 55 CR# vcMMAE 55 ON #.Na 55 oncology indications 55 CTAP# Capsules 55 Azixa 55 Aplidin 55 Met receptor tyrosine 55 Myelofibrosis 55 relapsed leukemia 55 neratinib 55 HDAC inhibitor 55 IgG1 antibody 55 tyrosine kinase inhibitor TKI 55 aflibercept VEGF Trap 55 hypereosinophilic syndrome 55 Genasense evaluating 55 TG# [001] 55 evaluating tivozanib 55 PXD# 55 molecularly targeted 55 leukemia CLL 55 cMET 55 carcinoma HCC 55 histone deacetylase HDAC 55 investigational compounds 55 systemic RNA interference 55 sorafenib Nexavar 55 adecatumumab 55 PKC# 55 OMP #M# 55 histone methyltransferases HMTs 55 oral JAK1 55 advanced carcinoid 55 ZFP Therapeutics 55 chronic eosinophilic leukemia 55 imetelstat 55 siRNA conjugates 55 obatoclax 55 lintuzumab 55 Sezary syndrome 55 sorafenib tablets 55 metastatic renal cell carcinoma 55 polycythemia vera PV 55 BRIM2 55 proteasome inhibitors 55 sunitinib malate 55 molecular imaging radiopharmaceuticals 55 PARP inhibitor 55 papillary renal cell carcinoma 55 HGS# 55 cilengitide 55 #,# +# 55 humanized antibody 55 PI3K inhibitor 55 MGd 55 adhesion molecule EpCAM expressing 55 tubulin inhibitor 55 Azedra 55 relapsed refractory multiple myeloma 55 refractory NSCLC 55 solid tumors 55 hA# 55 synthetic retinoid 55 selective inhibition 55 Seliciclib 55 depsipeptide 55 XL# inhibits 54 Transdrug ® nanoparticle 54 Tyrima 54 XmAb# 54 Allovectin 7 54 CBLC# 54 Preclinical studies suggest 54 patented Bioral R nanocochleate 54 preclinically 54 fallopian tube cancers 54 palifosfamide 54 lung pancreatic 54 CD# antibody [001] 54 Bezielle 54 JAK2 inhibitors 54 anticancer therapeutics 54 anti angiogenic 54 nab paclitaxel 54 TTR gene 54 polymerase inhibitors 54 Irinotecan 54 metastatic malignant 54 ganetespib 54 Neulasta ® 54 AP# [003] 54 PRTX 54 PI3K Akt 54 bioengineered novel 54 myeloproliferative disorders 54 potent antiproliferative 54 mTOR inhibitors 54 mTOR inhibitor 54 gastrointestinal stromal tumors 54 GSK # 54 Amrubicin 54 JAK2 inhibitor 54 refractory multiple myeloma 54 vidofludimus 54 visilizumab 54 T#I [002] 54 T#I mutant 54 Pathway Inhibitor 54 fibrotic disease 54 pancreatic prostate 54 humanised monoclonal antibody 54 demonstrated anti amnesic 54 JAK3 54 potent inhibitor 54 hematologic malignancies 54 Vidaza ® 54 essential thrombocythemia 54 Triapine 54 superficial bladder cancer 54 Imprime PGG 54 candidate Lovaxin C 54 ara C 54 cyclin dependent kinases CDKs 54 siRNA compounds 54 bafetinib 54 SCCHN 54 sorafenib Nexavar ® 53 modulate ion channel 53 PI3 K 53 ofatumumab 53 BiTE antibody 53 castration resistant prostate cancer 53 APOPTONE 53 relapsed refractory 53 mapatumumab 53 MEK inhibitor RDEA# 53 Cloretazine 53 Voreloxin 53 forodesine 53 inhibit EGFR 53 ThermoDox R 53 kinase inhibitors 53 trastuzumab Herceptin ® 53 metastatic neuroendocrine tumors 53 docetaxel Taxotere 53 metastatic pancreatic 53 K ras mutations 53 sunitinib Sutent 53 INCB# [001] 53 talactoferrin 53 HCV protease 53 imatinib Gleevec 53 hematologic disorders 53 tumors GIST 53 cell malignancies 53 Metastatic 53 EGFR inhibitors 53 induces apoptosis 53 prostate cancer HRPC 53 NovaBay Aganocide compounds 53 EGF receptor 53 IKK epsilon 53 oritavancin 53 vinca alkaloids 53 CA4P 53 Vorinostat 53 ENMD 53 metastatic renal cell 53 BCR ABL 53 Sudhir Agrawal D.Phil 53 #,# +# pips #,# [001] 53 V#F mutation 53 belinostat 53 tanespimycin 53 antiangiogenic 53 MOZOBIL 53 IMC A# 53 XL# [003] 53 seliciclib 53 pancreatic colon 53 MGCD# [001] 53 Evoltra ® 53 CD# expressing 53 demonstrated antitumor activity 53 tumor vasculature 53 sapacitabine 53 neurodegenerative diseases Alzheimer disease 53 flu mAb 53 Kit CD# positive 53 HspE7 53 adenoviral 53 antimitotic 53 mRCC 53 Hodgkin lymphoma HL 53 PI3K inhibitors 53 histologies 53 xenograft tumor models 53 virus HCV infection 52 paclitaxel Taxol ® 52 immune modulator 52 Allovectin 7 ® 52 EGFr 52 EGFR pathway 52 selectively induce apoptosis 52 EGFR tyrosine kinase inhibitors 52 paclitaxel Taxol 52 dose escalation study 52 REOLYSIN ® 52 multiple myeloma MM 52 neuroendocrine cancers 52 Acute Myeloid Leukemia AML 52 #,# +# pips [002] 52 lung carcinomas 52 Nexavar sorafenib 52 PEG Interferon lambda 52 TTR amyloidosis 52 TREANDA 52 body AVI antiviral 52 Ceflatonin 52 hepatocellular carcinoma 52 haematological malignancies 52 Debio 52 preclinical xenograft models 52 gastrointestinal stromal tumors GISTs 52 KRAS wild 52 human tumor xenografts 52 cancer mCRC 52 fluoropyrimidine 52 unresectable tumors 52 skeletal metastases 52 CCR2 52 metastatic malignant melanoma 52 gastric pancreatic 52 Glioblastoma Multiforme 52 deforolimus 52 basal cell carcinoma squamous 52 #ME# 52 myelodysplastic syndromes MDS 52 biomarkers predictive 52 RDEA# potent 52 Ischemic Spastic Paraplegia Traumatic 52 ADI PEG 52 calcineurin inhibitors 52 panitumumab Vectibix 52 CLL SLL 52 imatinib resistant 52 IGF IR 52 lymphoma CTCL 52 cetuximab Erbitux ® 52 selectively inhibit replication 52 Metastatic breast cancer 52 Phase Ib 52 Hepatocellular Carcinoma HCC 52 regulate therapeutically important 52 gastrointestinal stromal tumors GIST 52 SAR# [004] 52 docetaxel Taxotere ® 52 luteinizing hormone releasing 52 milatuzumab 52 PEGylated 52 Amigal 52 CUDC 52 metastatic relapsed 52 #,# +# pips [001] 52 histone deacetylase inhibitor 52 cisplatin resistant 52 PDGF receptor 52 lymphoid malignancies 52 eculizumab 52 treats acute lymphoblastic 52 pro angiogenic 52 antitumor activity 52 immunological diseases 52 INCB# [003] 51 IL #E 51 noninfectious uveitis 51 recurrent glioblastoma multiforme 51 CFTR corrector 51 docetaxel chemotherapy 51 PF # [001] 51 colorectal carcinoma 51 cediranib 51 HepDirect prodrug 51 immunomodulatory 51 uses NEUGENE antisense 51 Toxicities 51 EGFRvIII 51 EpCAM 51 metastatic renal 51 AA amyloidosis 51 ASA# 51 tumor necrosis 51 investigational therapies 51 relapsed multiple myeloma 51 EOquin 51 biliary tract cancer 51 Zolinza 51 INCB# [002] 51 androgen receptor AR 51 non metastatic osteosarcoma 51 anticancer therapy 51 chemotherapeutic agent 51 Neuradiab 51 JAK2 51 DAVANAT 51 carcinoid syndrome diabetes 51 azacytidine 51 stage IIIB 51 Gleevec resistant 51 non squamous 51 potently inhibited 51 Hsp# inhibitors 51 CYT# 51 ORTHOVISC ® mini 51 multiple sclerosis rheumatoid arthritis 51 tyrosine kinase inhibitors 51 refractory metastatic 51 EOquin TM 51 BRAF mutation 51 glufosfamide 51 axitinib 51 hepatocellular carcinoma HCC 51 gastrointestinal stromal tumor GIST 51 AT1R 51 neuroendocrine tumors 51 pralatrexate 51 talabostat 51 Cutaneous T 51 panobinostat 51 anticancer therapies 51 gamma secretase inhibitor 51 TACI Ig 51 idarubicin 51 HuMax CD4 51 commercialize deforolimus 51 prostate cancer CRPC 51 uPA 51 cytokine refractory 51 VEGF inhibitors 51 platinum refractory 51 refractory Hodgkin lymphoma 51 engineered anticoagulant 51 taxane chemotherapy 51 survivin 51 acute GvHD 51 #,# +# pips #,# [002] 51 chemotherapeutic drug 51 elacytarabine 51 vorinostat 51 YONDELIS 51 dacetuzumab 51 anticancer agent 51 non resectable 51 refractory AML 51 multikinase inhibitor 51 IMGN# 51 systemic lupus erythematosus SLE 51 activating mutations 51 relapsed ovarian cancer 51 anti leukemic 51 HER3 51 NexVas TM 51 MAb 50 ischemic tissues 50 unresectable stage 50 chronic myelogenous leukemia CML 50 recurrent glioblastoma 50 pancreatic adenocarcinoma 50 preclinical models 50 ovarian lung 50 CHOP chemotherapy 50 AEGR 50 chronic HCV infection 50 peptide antigens 50 anti EGFR antibody 50 malignant pleural mesothelioma 50 Preclinical studies 50 imatinib mesylate 50 fatty acid amide hydrolase 50 Phase #/#a trial 50 GPNMB 50 refractory CTCL 50 SCI readership 50 anticancer agents 50 Marqibo 50 Tamibarotene 50 induce apoptosis 50 PARP inhibitors 50 hematologic cancers 50 deCODE AF TM 50 cytolytic 50 syngeneic 50 cytotoxic chemotherapy 50 diabetic nephropathy 50 metastatic GIST 50 prostate cancer AIPC 50 OHR/AVR# 50 intratumoral injection 50 erythropoietic 50 INGN 50 CD# antigen 50 elesclomol 50 resistant ovarian cancer 50 androgen independent 50 HDAC inhibitors 50 KRAS mutant 50 PLX# 50 gastrointestinal stromal tumor 50 pancreatic ovarian 50 aurora kinase inhibitor 50 haematopoietic 50 anti fibrotic 50 0 SHOTS OFF 50 molecular biomarkers 50 developing calcitonin 50 Pemetrexed 50 RH1 50 HCV genotypes 50 dacarbazine DTIC 50 antitumor 50 Fludara 50 indications Cytokinetics 50 liver metastases 50 intracellular protein 50 5 fluorouracil 50 systemic lupus erythematosus 50 huN# DM1 50 risk reward #:#.# 50 BrachySil TM 50 cerebrospinal fluid CSF 50 Nanobodies 50 voreloxin 50 breast carcinomas 50 BCG refractory 50 idiopathic pulmonary fibrosis IPF 50 lupus nephritis 50 refractory acute myeloid 50 interferon IFN 50 cytotoxic agents 49 myelodysplastic syndrome MDS 49 genomes metagenomics RNA 49 Tarceva TM 49 Tavocept 49 relapsing remitting multiple sclerosis 49 LBH# 49 basal cell carcinoma BCC 49 location Siskovic 49 small molecule 49 PKCi 49 metastatic bladder 49 squamous 49 tumor metastases 49 Sharps Compliance focuses 49 metastatic gastric 49 alkylating agents 49 HRPC 49 TNFa 49 temsirolimus 49 non squamous NSCLC 49 perifosine 49 metastatic breast 49 relapsing multiple sclerosis 49 PEGPH# 49 specific chemokine receptors 49 AIDS prophylaxis congestive 49 including PCMag.com eWEEK.com 49 dose cohorts 49 anti angiogenic therapy 49 +# pips #,# 49 dose limiting toxicities 49 IGF 1R 49 mCRC 49 microtubule targeting 49 systemic lupus erythematosus lupus 49 IV NSCLC 49 Li Fraumeni Syndrome 49 Hedgehog signaling pathway 49 MPS IVA 49 mouse xenograft models 49 trabectedin 49 reliably caucused 49 TORISEL 49 amrubicin 49 Alpharadin 49 tumor antigen 49 bendamustine 49 Everolimus 49 tamibarotene 49 immune mediated 49 SUTENT 49 AGGRASTAT R tirofiban hydrochloride 49 c MYC 49 Here seeming paradox 49 carfilzomib 49 tumor microenvironment 49 relapsed CLL 49 factor G CSF 49 DLBCL 49 breast ovarian 49 ixabepilone 49 TTF Therapy 49 IV metastatic melanoma 49 CanAg 49 gastric adenocarcinoma 49 GISTs 49 opioid induced constipation OIC 49 interpret wiretapped conversations 49 Genasense ® 49 medullary thyroid cancer 49 NF kB pathway 49 COLAL PRED ® 49 colorectal lung 48 Alessandro Riva 48 Ganetespib 48 metastatic RCC 48 neuronal nicotinic receptors NNRs 48 unresectable 48 chronic lymphocytic leukemia CLL 48 situ CIS 48 indolent NHL 48 hematological malignancy 48 T#I mutation 48 gamma amino butyric 48 ovarian carcinoma 48 pegfilgrastim 48 pancreatic carcinoma 48 myeloproliferative neoplasms 48 anthrax botulism typhoid 48 B CLL 48 prostate carcinoma 48 hormone refractory prostate cancer 48 chemotherapeutic agents 48 bleomycin 48 MLL AF9 48 bortezomib Velcade 48 CTGF 48 liposomal doxorubicin 48 Telintra 48 Ampakine compounds 48 taxane 48 factor receptor 48 dihydrofolate reductase DHFR 48 infill submarkets 48 decitabine 48 dasatinib 48 tesetaxel 48 taxanes 48 immunotherapies 48 acute leukemias 48 Glioblastoma multiforme GBM 48 hedgehog pathway 48 Hedgehog pathway 48 Podtrac survey 48 cervical carcinoma 48 bone metastases 48 NSCLC 48 taxane therapy 48 advanced hepatocellular carcinoma 48 recurrent GBM 48 acute coronary syndromes ACS 48 CMV disease 48 HCV 48 gemcitabine carboplatin 48 cell lymphoma ALCL 48 TRISENOX 48 toxicogenomic assessment 48 cholangiocarcinoma 48 differentiated thyroid 48 #T# tumor 48 resectable 48 carcinoid 48 pancreatic islet cell 48 MALT lymphoma 48 Mantle Cell Lymphoma 48 nonsmall cell lung cancer 48 retaspimycin hydrochloride 48 inhibiting tumor 48 lymphoma subtypes 48 cyclin E 48 refractory indolent non 48 anthrax botulism tuberculosis typhoid 48 sarcomatoid 48 anti angiogenic agents 48 chemotherapeutics 48 chemotherapeutic 48 T DM1 48 relapsed SCLC 47 Xcytrin 47 Diabetic macular edema 47 trans retinoic acid 47 interferon alfa 2a 47 adenocarcinomas 47 histological subtypes 47 hypercalcemia 47 HER2 receptor 47 hematopoietic cell 47 peritoneal carcinomatosis 47 stranded LNA 47 heavily pretreated 47 Current Lm vaccines 47 purinergic receptors P#X# 47 selectively modulate 47 colorectal pancreatic 47 myelofibrosis MF 47 epithelial cancers 47 prostate cancer mCRPC 47 mCRC patients 47 MMP inhibitors 47 gemcitabine chemotherapy 47 nucleolin 47 soft tissue sarcomas 47 recurrent ovarian cancer 47 acute myeloid leukemia AML 47 colon carcinoma 47 Zeeks.com 47 refractory metastatic colorectal cancer 47 smallpox SIGA 47 etoposide 47 tumor hypoxia 47 pediatric acute lymphoblastic 47 deacetylase inhibitors 47 bone metastasis 47 fallopian tube carcinoma 47 colorectal adenocarcinoma 47 inflammatory diseases 47 nasopharyngeal carcinoma 47 HIF 1α 47 IV melanoma 47 grade glioma 47 follicular lymphoma FL 47 oncology metabolic disorders 47 Pericones property 47 ActiveVideo combines Web 47 small lymphocytic lymphoma 47 recurrent malignant glioma 47 leukemia ALL 47 vinorelbine 47 isoform selective inhibitors 47 antibiotics antifungals 47 neoplastic 47 acute myelogenous leukemia AML 47 ADVEXIN 47 refractory CLL 47 colorectal gastric 47 blinatumomab 47 gastric carcinoma 47 olaparib 47 TKI therapy 47 HuCNS SC cells 47 standard chemotherapy regimens 47 astrocytoma 46 cell lung cancer 46 myelofibrosis 46 CXCR4 46 ponatinib 46 metastatic cancers 46 metastatic melanoma 46 CD# [002] 46 areas oncology endocrinology 46 Dede Ayew headed 46 oncoproteins 46 Crucell genetically engineered 46 chronic myeloid leukemia CML 46 gemcitabine 46 PC# cells 46 orthotopic 46 mutated KRAS gene 46 endostatin 46 tumor antigens 46 mutational status 46 TACE 46 gastrointestinal infectious 46 lymphomas 46 metastatic prostate cancer 46 azacitidine 46 anti angiogenic drugs 46 imatinib therapy 46 intracellular targeting 46 anthrax tuberculosis typhoid 46 prostate breast 46 CD# receptor 46 concurrent chemoradiation 46 tyrosine kinase inhibitors TKIs 46 AGGRASTAT ® tirofiban hydrochloride 46 papillary 46 Follicular lymphoma 46 GAP #B# 46 vandetanib 46 cell acute lymphoblastic 46 prostate carcinomas 46 WT1 46 metastatic colorectal cancer 46 HER-2/neu 46 Cotara 46 refractory colorectal cancer 46 ADPKD 46 Al Arabyia TV 46 pituitary adenomas 46 nasopharyngeal cancer 46 interleukins 46 NexVas TM PR 46 clofarabine 46 circling warplanes bombed 46 FOLOTYN 46 radionuclide therapy 46 cytotoxic 46 prostate lung 46 proprietary attenuated Listeria 46 chemo resistant 46 pancreatic neuroendocrine tumors 46 GenWay 46 websites www.#uu.com 46 carcinomas 46 hepatocellular cancer 46 anti VEGF 45 monotherapy 45 Vectibix monotherapy 45 proteasome inhibitor bortezomib 45 chemotherapeutic regimens 45 GM CSF 45 include IXCs CLECs 45 protein receptors lectins 45 HAAH 45 recurrent glioblastoma multiforme GBM 45 fibrotic 45 sarcomas 45 genomics proteomics biosensors 45 irinotecan chemotherapy 45 malignant transformation 45 Cytoxan 45 precursor lesions 45 hematopoietic stem cell 45 decreasing bone resorption 45 HER2 positive cancers 45 squamous cell carcinoma SCC 45 DrFirst creates 45 hCG beta 45 EGFR mutation 45 mercenary apostate collaborators 45 renal tumors 45 CRACM 45 pancreatic NET 45 stage IIIB IV 45 activated lymphocytes 45 trastuzumab 45 Alzheimer disease frontotemporal dementia 45 vismodegib 45 ependymoma 45 papillary RCC 45 refractory PTCL 45 nonmetastatic 45 tumor xenografts 45 EphA2 45 trans retinoic acid ATRA 45 leukemia APL 45 MTDH 45 myelodysplastic syndromes 45 hematopoietic 45 advanced NSCLC 45 heavily pretreated patients 45 KIT mutations 45 glioblastoma cells 45 HIF PHI 45 serous ovarian cancer 45 colorectal liver metastases 45 myeloma cells 45 bortezomib 45 Ghazi Hanash leader 45 carcinoid tumors 45 temozolomide 45 neoplastic cells 45 mesothelin 44 spokesman Kazuo Tohmatsu 44 Reolysin 44 IGFBP 3 44 5 FU 44 GvHD 44 malignancies 44 colon lung 44 EGFR mutations 44 metastatic